Hepatitis B DNA quantification needs to be combined with other indicators to determine whether medication is needed. There is no direct correlation between the antiviral indication of hepatitis B and the quantification of DNA, and it is mainly necessary to combine with other conditions to make a comprehensive judgment. According to the guidelines for the prevention and treatment of chronic hepatitis B, it is recommended that antiviral treatment can be carried out if the serum HBV-DNA is positive, ALT is more than twice the normal value, and other causes are excluded. In addition, antiviral therapy is recommended for HBV-DNA-positive patients with compensated hepatitis B cirrhosis and hepatitis B surface antigen-positive patients with decompensated hepatitis B cirrhosis. Antiviral therapy is also recommended if HBV-DNA positivity is normal, but one of the following conditions is present: 1. histologic examination of the liver suggests significant inflammation or fibrosis. 2. a family history of hepatitis B cirrhosis or hepatitis B hepatocellular carcinoma and age greater than 30 years. 3. persistent normal ALT age greater than 30 years is recommended for non-invasive diagnostic techniques for liver fibrosis tests or liver histology in the presence of significant liver inflammation or fibrosis of the liver. 4. HBV-associated pulmonary manifestations such as hBV-associated glomerulonephritis.